Package Leaflet: Information for the Patient
Segluromet 2.5mg/850mg film-coated tablets
Segluromet 2.5mg/1000mg film-coated tablets
Segluromet 7.5mg/850mg film-coated tablets
Segluromet 7.5mg/1000mg film-coated tablets
ertugliflozin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Segluromet
Segluromet contains two active substances, ertugliflozin and metformin. Each one belongs to a group of medicines called "oral antidiabetics". These are medicines that are taken by mouth to treat diabetes.
What Segluromet is used for
How Segluromet works
What is type 2 diabetes?
Type 2 diabetes is a condition where your body does not make enough insulin or the insulin your body makes does not work as well as it should. This leads to high blood sugar levels. When this happens, it can cause serious medical problems like heart disease, kidney disease, blindness, and poor circulation.
Do not take Segluromet
Do not take Segluromet if you are affected by any of the above situations. If you are not sure, consult your doctor before taking Segluromet.
Warnings and precautions
Risk of lactic acidosis
Segluromet may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of lactic acidosis also increases in case of uncontrolled diabetes, severe infections, prolonged fasting, or alcohol consumption, dehydration (see additional information below), liver problems, and any condition in which a part of your body is not getting enough oxygen (such as acute and severe heart disease).
If you are affected by any of the above situations, consult your doctor for further guidance.
Consult your doctor immediately for guidance on what to do if:
Stop taking Segluromet for a short period of time if you have a condition that may be associated with dehydration(significant loss of body fluids) such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than usual. Consult your doctor for further guidance.
Stop taking Segluromet and contact a doctor or go to the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Consult your doctor, pharmacist, or nurse before starting and during treatment with Segluromet if you:
It is important that you regularly check your feet and follow the advice given by your healthcare professional on foot care.
Consult your doctor immediately if you experience a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus, with fever or general feeling of being unwell. These symptoms could be a sign of a rare but serious infection, including potentially life-threatening, called necrotizing fasciitis of the perineum or Fournier's gangrene, which destroys tissue under the skin. Fournier's gangrene should be treated immediately.
When this medicine is used in combination with insulin or medicines that increase insulin release from the pancreas, it may cause a drop in blood sugar levels (hypoglycemia). Your doctor may reduce the dose of your insulin or other medicines.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
If you need to undergo major surgery, you should stop taking Segluromet during and for some time after surgery. Your doctor will decide when you should stop and restart your treatment with Segluromet.
During treatment with Segluromet, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person or if your kidney function is worsening.
Glucose in urine
Due to the way Segluromet works, your urine will test positive for glucose (sugar) while you are taking this medicine.
Children and adolescents
Children and adolescents under 18 years of age should not take this medicine. It is not known if this medicine is safe and effective when used in children and adolescents under 18 years of age.
Other medicines and Segluromet
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
You may need to have more frequent blood tests to check your blood sugar levels and kidney function, or your doctor may need to adjust the dose of Segluromet. In particular, tell your doctor:
If you are affected by any of the above situations (or are unsure), tell your doctor.
If you need to receive an injection into your bloodstream of a contrast medium that contains iodine, for example, for an X-ray or scan, you should stop taking Segluromet before or at the time of the injection. Your doctor will decide when you should stop and restart your treatment with Segluromet.
Taking Segluromet with alcohol
Avoid excessive alcohol consumption while taking Segluromet, as this may increase the risk of lactic acidosis (see section "Warnings and precautions").
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known if Segluromet is harmful to the unborn baby. If you are pregnant, consult your doctor about the best way to control your blood sugar levels during pregnancy. You should not use Segluromet if you are pregnant.
It is not known if Segluromet passes into breast milk. Consult your doctor about the best way to feed your baby if you are taking this medicine. You should not use Segluromet if you are breastfeeding.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas may cause a drop in blood sugar levels (hypoglycemia), which can cause symptoms such as trembling, sweating, or changes in vision and may affect your ability to drive or use machines. Do not drive or operate tools or machines if you feel dizzy while taking Segluromet.
Segluromet contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, consult your doctor or pharmacist.
How much to take
How to take this medicine
If you take more Segluromet than you should
If you take more Segluromet than you should, consult a doctor or pharmacist immediately.
If you forget to take Segluromet
What you should do if you miss a dose depends on how much time is left before your next dose.
Do not take a double dose (two doses at the same time) to make up for missed doses.
If you stop taking Segluromet
Do not stop taking this medicine without consulting your doctor. If you stop taking the medicine, your blood sugar levels may increase.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Contact a doctor or go to the nearest hospital immediately if you experience any of the following serious adverse effects:
Lactic Acidosis (very rare, may affect up to 1 in 10,000 people)
Segluromet may cause a very rare but very serious adverse effect called lactic acidosis (see section “Warnings and Precautions”). If this happens, stop taking Segluromet and contact a doctor or go to the nearest hospital immediately, as lactic acidosis can lead to coma.
Diabetic Ketoacidosis (rare, may affect up to 1 in 1,000 people)
The signs of diabetic ketoacidosis are listed below (also see the section “Warnings and Precautions”):
This can occur regardless of blood glucose levels. Your doctor may decide to temporarily or permanently discontinue your treatment with Segluromet.
Necrotizing Fasciitis of the Perineum or Fournier's Gangrene (frequency not known, cannot be estimated from available data)
A severe infection of the soft tissues of the genitals or the area between the genitals and the anus (see the section “Warnings and Precautions” for symptoms).
If you notice any of the aforementioned adverse effects, contact a doctor or go to the nearest hospital immediately.
Contact your doctor as soon as possible if you notice the following adverse effects:
Urinary Tract Infection (very common, may affect more than 1 in 10 people)
The signs of urinary tract infection are:
Although it is rare, if you have a fever or see blood in your urine, inform your doctor immediately.
Dehydration (excessive loss of body water; common, may affect up to 1 in 10 people)
The symptoms of dehydration include:
You are more likely to become dehydrated if you:
Low Blood Sugar (Hypoglycemia; common)
Your doctor will tell you how to treat low blood sugar and what to do if you experience any of the following symptoms or signs. Your doctor may reduce the dose of your insulin or other diabetes medications.
The signs and symptoms of low blood sugar may include:
If you notice any of the aforementioned adverse effects, contact your doctor as soon as possible.
Other Adverse Effects Include:
Very Common
Common
Uncommon (may affect up to 1 in 100 people)
Very Rare
Frequency Not Known
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the blister pack and carton after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Segluromet
Appearance of the Product and Package Contents
Segluromet is available in Alu/PVC/PA/Alu blisters. The pack sizes are 14, 28, 56, 60, 168, 180, and 196 film-coated tablets in non-perforated blisters and 30 film-coated tablets in perforated unit-dose blisters.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: + 370 5 2780 247 dpoc_lithuania@msd.com |
Luxembourg MSD Belgium Tel: +32(0)27766211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: + 36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: + 45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: + 386 1 520 4201 msd_slovenia@merck.com |
Iceland Vistor ehf. Tel: + 354 535 7000 | Slovakia Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: + 46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67025300 dpoc.latvia@msd.com |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
The average price of SEGLUROMET 7.5 mg/1000 mg FILM-COATED TABLETS in October, 2025 is around 47.46 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.